On May 31, Center Laboratories’s subsidiary Glac Biotech Biotech participated in an investor forum hosted by Huanan Financial Holdings, marking its first appearance since pausing its OTC public offering in 2019 and completing privatization in 2024. In recent years, Glac Biotech has shifted its focus from China to the global market due to geopolitical factors. The company is dedicated to providing top-tier probiotic solutions for leading global nutrition companies, leveraging high-quality bacterial powders, a diverse product range, and superior manufacturing processes. At the forum, Glac Biotech reported impressive growth, with revenue increasing from 258 million NTD in 2020 to 441 million NTD in 2023, showcasing four consecutive years of strong revenue growth.
Looking ahead, Glac Biotech expressed optimism about this year’s orders. As of April, revenue had nearly reached 200 million NTD, with orders in hand amounting to 270 million NTD. The company expects annual revenue to surpass 500 million NTD, with an EBITDA of 33.8 million NTD, representing a year-on-year increase of 254%. With robust cash flow, Glac Biotech is on the verge of turning profitable. The majority of revenue is derived from international markets, with continuous and steady expansion.
Founded 16 years ago, Glac Biotech Biotech, under the leadership of Chairman Lin Rongjin, has developed clinically proven probiotic products based on scientific evidence and has pioneered the development of postbiotic products. In a few short years, Glac Biotech has surpassed many established domestic and international probiotic brands, winning numerous health ingredient awards. The company is the first and only in the region to offer probiotics approved for infant consumption in China and, in May, became the sole recipient in Taiwan of the U.S. GRAS certification for probiotics. This recognition not only solidifies Glac Biotech’s leading position in the Taiwanese probiotic market but also brings international acclaim to the group.
Glac Biotech’s success is attributed to its continuous efforts to explore new markets and establish new collaboration models with major international clients. By leveraging economies of scale to increase production capacity, the company has significantly reduced costs and enhanced market competitiveness. General Manager Huang Shenghong (pictured) stated that the company’s advanced R&D capabilities and clear market strategies, along with targeted customer acquisition efforts, are expected to drive revenue past 500 million NTD by year-end.
The international probiotic market is experiencing rapid growth, with a projected compound annual growth rate of 14% from 2023 to 2030. As the global population ages and health awareness rises, the demand for natural, non-pharmaceutical solutions is expected to grow, further boosting the probiotic market. Center Laboratories’s 100% acquisition of Glac Biotech in the first half of 2024, following its major investment in Ausnutria Dairy, underscores its commitment to the health sector. Center Laboratories is confident that Glac Biotech Biotech’s solid foundation and strength will enable it to quickly gain momentum in the international market and rise rapidly in the burgeoning probiotic industry.
Resource (mandarin)
